Pepper Bio Market Research Report

Company Overview

Name

Pepper Bio

Mission of the Company

Pepper Bio develops cures with confidence by finding new targets, predicting the best patients, and knowing how well new drugs will work before they’re tested in humans. The company uses transomic technology that leverages functional data to develop treatments for diseases previously thought to be untreatable.

Founded

2020

Founders

Samantha Dale Strasser, PhD

Role: CSO & Co-Founder

Background: PhD, MIT

Jon Hu

Role: CEO & Co-Founder

Background: MBA, Harvard Business School

Key People

Christopher Nicholson, PhD

Role: Head, Biology

Background: PhD, Newcastle University

Caitlin Brown, PhD

Role: Head, Business Development

Background: PhD, Brown University

Samuel Roth, PhD

Role: Senior Computational Biologist

Background: PhD, University of California San Diego

Simon Fricker, PhD

Role: Chief Development Officer

Background: PhD, University of Warwick

Headquarters

Boston, MA

Number of Employees

2-10 employees

Revenue

No information is available

Notable Aspects

Pepper Bio is known for applying novel full-stack transomics to drug research and discovery, ultimately driving repeatable commercial success.

Products

Product Offering

Platform:

Pepper Bio Platform

High Level Description

Pepper Bio’s platform uses a truly transomic analysis that integrates phosphoproteomics, proteomics, transcriptomics, and genomics to create a whole-stack solution to common drug discovery challenges. This approach aims to reveal actionable insights that are often missed in traditional methods.

Key Features

Global Data Capture:

Captures the full picture of disease biology and drug mechanism with global omic data.

Functional Analysis:

Provides detailed insights into biological processes through proteomic and phosphoproteomic data.

Causative Insights:

Identifies actual biological drivers, not just correlations, through integrated analysis.

End-to-End Drug Discovery:

Enables faster and more precise drug development with technology that better informs almost every stage of the process.

Commercial Opportunities:

Identifies new possibilities for biomarker identification, drug combinations, target identification, patient stratification, indication expansion, and lead optimization.

Recent Developments

Recent Key Events

1. Seed Funding:

Raised $6.5 million in seed funding in December 2023, led by NFX and included other investors like Silverton Partners, Merck Digital Sciences Studio, Mana Ventures, Tensility Ventures, and VSC Ventures.

2. Partnerships:

G1 Therapeutics and Pepper Bio Announce Global License Agreement for Lerociclib - On May 1, 2024, Pepper Bio gained exclusive rights for the clinical development, regulatory submissions, and commercialization of Lerociclib in the US, Europe, Japan, and other global markets excluding Asia-Pacific.

Novo Nordisk Collaboration:

Launched a collaboration with Novo Nordisk’s Bio Innovation Hub through its Co-Creation Greenhouse Program to increase understanding of healthy muscle growth using the COMPASS transomic platform.

3. Development Milestones:

Therapeutic Identification:

Identified lerociclib as an efficacious therapeutic in treating Hepatocellular Carcinoma (HCC), validated through subsequent testing in pre-clinical in vivo models.

Publication and Presentation:

Published research and presented findings at conferences such as AACR 2024, showcasing their approach to tackling ‘undruggable’ targets using machine learning-driven transomics.

New Features Added

No specific new features were added to the existing products based on the recent information.

New Products Launched

No new products launched recently besides the continual development within their transomic platform and the partnership expansions indicated above.

Partnerships

G1 Therapeutics for Lerociclib development and commercialization.

Novo Nordisk’s Bio Innovation Hub to research healthy muscle growth through the Co-Creation Greenhouse Program.

This comprehensive report provides key insights into Pepper Bio’s operations, technological foundations, recent developments, and strategic partnerships which highlight the company's innovative approach to drug discovery and development.